Dokumendiregister | Ravimiamet |
Viit | REP-1/4002-1 |
Registreeritud | 04.11.2024 |
Sünkroonitud | 05.11.2024 |
Liik | Sissetulev kiri |
Funktsioon | REP Euroopa Farmakopöaga seotud asjaajamine |
Sari | REP-1 Euroopa Farmakopöa alane kirjavahetus |
Toimik | REP-1/2024 |
Juurdepääsupiirang | Avalik |
Juurdepääsupiirang | |
Adressaat | European Directorate for the Quality of Medicines & HealthCare |
Saabumis/saatmisviis | European Directorate for the Quality of Medicines & HealthCare |
Vastutaja | Signe Leito (RA, Labor) |
Originaal | Ava uues aknas |
1
Signe Leito
Saatja: [email protected] Saatmisaeg: teisipäev, 15. oktoober 2024 16:44 Adressaat: Signe Leito Teema: Survey on Deletion of the revision of Methylprednisolone hydrogen succinate 1131 from the WP, Group 10B: EDQM-2024-04187-mail
Please make sure to include in any reply our mail reference: EDQM-2024-04187-mail **************************************************************************** For the attention of NPAs Copy: Presidium Dear Colleagues, Please find below the link to a survey being carried out concerning the proposed deletion of the revision of Methylprednisolone hydrogen succinate (1131) from the work programme (Group10B). In order to have access to the survey, please copy and paste this link into your Internet browser: https://survey.edqm.eu/index.php?r=survey/index&sid=526488&lang=en Deadline for replies: 5 November 2024 Thank you. With kind regards On behalf of Sylvina Iossiphova ___ Villy Nikolova Administrative Support Assistant European Pharmacopoeia Department EDQM Council of Europe
Tähelepanu! Tegemist on väljastpoolt asutust saabunud kirjaga. Tundmatu saatja korral palume linke ja faile mitte avada.
2
Tel.: +33 (0)3 90 21 64 63 / Fax: +33 (0)3 88 41 27 71 https://www.edqm.eu / https://www.edqm.eu/store Stay connected with the EDQM
**************************************************************************** Please make sure to include in any reply our mail reference: EDQM-2024-04187-mail
Nimi | K.p. | Δ | Viit | Tüüp | Org | Osapooled |
---|---|---|---|---|---|---|
Farmakopöa töökava asjus | 04.11.2024 | 1 | REP-1/4002-2 | Väljaminev kiri | ra | European Directorate for the Quality of Medicines & HealthCare |